Tgf-beta binding antibodies

Abstract

The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-β1, TGF-β2, and TGF-β3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal.

1 - 11 . (canceled) 
     
     
         12 . A method of treating a cell proliferative disorder, comprising administering to a subject in need thereof an effective amount of a monoclonal antibody that binds TGF-Beta 1, 2, and 3, wherein each heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 69, and each light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 45. 
     
     
         13 . The method of  claim 12 , wherein said cell proliferative disorder is selected from the group consisting of myelodysplastic syndrome/myeloproliferative disorder, breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, multiple myeloma, colorectal cancer, hairy cell leukemia, chronic myelogenous leukemia, and acute myelogenous leukemia. 
     
     
         14 . A method of treating a cell proliferative disorder, comprising administering to a subject in need thereof an effective amount of a monoclonal antibody that binds TGF-Beta 1, 2, and 3, wherein each heavy chain comprises the amino acid sequence shown in SEQ ID NO: 81 and each light chain comprises the amino acid sequence shown in SEQ ID NO: 80. 
     
     
         15 . The method of  claim 14 , wherein said cell proliferative disorder is selected from the group consisting of myelodysplastic syndrome/myeloproliferative disorder, breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, multiple myeloma, colorectal cancer, hairy cell leukemia, chronic myelogenous leukemia, and acute myelogenous leukemia.